Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Consensus Rating of “Buy” by Brokerages

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have earned a consensus rating of “Buy” from the nine brokerages that are presently covering the firm, MarketBeat reports. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $15.97.

A number of equities research analysts have commented on VYGR shares. Cantor Fitzgerald started coverage on shares of Voyager Therapeutics in a report on Friday. They set an “overweight” rating and a $5.73 price objective on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $14.00 target price on shares of Voyager Therapeutics in a research note on Thursday, November 14th. Citigroup started coverage on shares of Voyager Therapeutics in a research note on Monday, December 2nd. They issued a “buy” rating and a $12.00 target price on the stock. Leerink Partnrs raised shares of Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 16th. Finally, StockNews.com lowered shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 13th.

Voyager Therapeutics Stock Down 4.9 %

Shares of NASDAQ:VYGR opened at $5.45 on Friday. Voyager Therapeutics has a 12 month low of $5.19 and a 12 month high of $10.66. The company’s 50-day moving average price is $6.13 and its two-hundred day moving average price is $6.84. The firm has a market cap of $297.71 million, a P/E ratio of 7.68 and a beta of 0.93.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The firm had revenue of $24.63 million for the quarter, compared to analyst estimates of $12.63 million. During the same quarter in the prior year, the firm earned ($0.59) EPS. As a group, equities analysts predict that Voyager Therapeutics will post -0.89 earnings per share for the current fiscal year.

Insider Activity at Voyager Therapeutics

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of Voyager Therapeutics stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total value of $36,725.00. Following the transaction, the chief operating officer now owns 112,328 shares of the company’s stock, valued at approximately $634,653.20. The trade was a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 4.53% of the stock is currently owned by corporate insiders.

Institutional Trading of Voyager Therapeutics

A number of institutional investors have recently made changes to their positions in VYGR. Bank of New York Mellon Corp lifted its position in shares of Voyager Therapeutics by 17.7% in the second quarter. Bank of New York Mellon Corp now owns 294,420 shares of the company’s stock worth $2,329,000 after purchasing an additional 44,289 shares in the last quarter. Commonwealth Equity Services LLC lifted its position in shares of Voyager Therapeutics by 36.8% in the second quarter. Commonwealth Equity Services LLC now owns 77,905 shares of the company’s stock worth $616,000 after purchasing an additional 20,950 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Voyager Therapeutics by 56.0% in the second quarter. Rhumbline Advisers now owns 72,461 shares of the company’s stock worth $573,000 after purchasing an additional 26,014 shares in the last quarter. Victory Capital Management Inc. lifted its position in shares of Voyager Therapeutics by 14.5% in the second quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock worth $102,000 after purchasing an additional 1,630 shares in the last quarter. Finally, American Century Companies Inc. lifted its position in shares of Voyager Therapeutics by 32.4% in the second quarter. American Century Companies Inc. now owns 1,019,332 shares of the company’s stock worth $8,063,000 after purchasing an additional 249,659 shares in the last quarter. Institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.